WASHINGTON — A new “right-to-try” bill hurtling toward a House vote this week would give the Food and Drug Administration some oversight of experimental treatments permitted under a new process, but critics warn that it would still undermine the agency’s role in protecting patients.

The new legislation, from House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), is the latest salvo in the effort to create a new pathway for patients with terminal illness to access experimental therapies. The House of Representatives is set to vote on the measure Tuesday, after which it will head back to the Senate for further consideration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy